These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21983344)

  • 21. Natriuretic peptides modulate nitric oxide synthesis in cytokine-stimulated cardiac myocytes.
    Yamamoto K; Ikeda U; Shimada K
    J Mol Cell Cardiol; 1997 Sep; 29(9):2375-82. PubMed ID: 9299361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Erythropoietin inhibits angiotensin II induced cardiomyocyte hypertrophy in vitro via activating PI3K/Akt-eNOS pathway].
    Wen Y; Ma YX; Zhang XJ; Hong LF; Feng DY; Lu ZH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 May; 37(5):436-40. PubMed ID: 19781221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart.
    Kinoshita H; Kuwahara K; Nishida M; Jian Z; Rong X; Kiyonaka S; Kuwabara Y; Kurose H; Inoue R; Mori Y; Li Y; Nakagawa Y; Usami S; Fujiwara M; Yamada Y; Minami T; Ueshima K; Nakao K
    Circ Res; 2010 Jun; 106(12):1849-60. PubMed ID: 20448219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B-type natriuretic peptide attenuates cardiac hypertrophy via the transforming growth factor-ß1/smad7 pathway in vivo and in vitro.
    He JG; Chen YL; Chen BL; Huang YY; Yao FJ; Chen SL; Dong YG
    Clin Exp Pharmacol Physiol; 2010 Mar; 37(3):283-9. PubMed ID: 19719752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
    Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
    Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Opening of ATP-sensitive potassium channel attenuates cardiac remodeling induced by chronic inhibition of nitric oxide synthesis].
    Sanada S; Node K; Asanuma H; Ogita H; Takashima S; Minamino T; Asakura M; Hori M; Kitakaze M
    J Cardiol; 2003 Jan; 41(1):43-4. PubMed ID: 12564115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats.
    Zanfolin M; Faro R; Araujo EG; Guaraldo AM; Antunes E; De Nucci G
    J Cardiovasc Pharmacol; 2006 Mar; 47(3):391-5. PubMed ID: 16633081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure.
    Gallo P; Latronico MV; Gallo P; Grimaldi S; Borgia F; Todaro M; Jones P; Gallinari P; De Francesco R; Ciliberto G; Steinkühler C; Esposito G; Condorelli G
    Cardiovasc Res; 2008 Dec; 80(3):416-24. PubMed ID: 18697792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antihypertrophic effects of adiponectin on cardiomyocytes are associated with the inhibition of heparin-binding epidermal growth factor signaling.
    Liao Y; Xuan W; Zhao J; Bin J; Zhao H; Asakura M; Funahashi T; Takashima S; Kitakaze M
    Biochem Biophys Res Commun; 2010 Mar; 393(3):519-25. PubMed ID: 20152812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
    Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
    Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disruption of inhibitory G-proteins mediates a reduction in atrial beta-adrenergic signaling by enhancing eNOS expression.
    Danson EJ; Zhang YH; Sears CE; Edwards AR; Casadei B; Paterson DJ
    Cardiovasc Res; 2005 Sep; 67(4):613-23. PubMed ID: 15936740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of olmesartan on Apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure.
    Fukushima H; Kobayashi N; Takeshima H; Koguchi W; Ishimitsu T
    J Cardiovasc Pharmacol; 2010 Jan; 55(1):83-8. PubMed ID: 19904215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polydatin prevents hypertrophy in phenylephrine induced neonatal mouse cardiomyocytes and pressure-overload mouse models.
    Dong M; Ding W; Liao Y; Liu Y; Yan D; Zhang Y; Wang R; Zheng N; Liu S; Liu J
    Eur J Pharmacol; 2015 Jan; 746():186-97. PubMed ID: 25449040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombomodulin is upregulated in cardiomyocytes during cardiac hypertrophy and prevents the progression of contractile dysfunction.
    Li YH; Chung HC; Luo CY; Chao TH; Shyu KG; Shi GY; Wu HL
    J Card Fail; 2010 Dec; 16(12):980-90. PubMed ID: 21111988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exercise preconditioning attenuates pressure overload-induced pathological cardiac hypertrophy.
    Xu T; Tang H; Zhang B; Cai C; Liu X; Han Q; Zou L
    Int J Clin Exp Pathol; 2015; 8(1):530-40. PubMed ID: 25755743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of atenolol and nifedipine on nitric-oxide deficient cardiomyocyte hypertrophy and expression of the cardio-endocrine peptide intermedin and its receptor components.
    Bell D; Zhao YY; Devine AB; McDermott BJ
    Cell Physiol Biochem; 2008; 21(1-3):203-14. PubMed ID: 18209487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of angiotensin II and l-NG-nitroarginine methyl ester exacerbates mitochondrial dysfunction and oxidative stress to cause heart failure.
    Hamilton DJ; Zhang A; Li S; Cao TN; Smith JA; Vedula I; Cordero-Reyes AM; Youker KA; Torre-Amione G; Gupte AA
    Am J Physiol Heart Circ Physiol; 2016 Mar; 310(6):H667-80. PubMed ID: 26747502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertrophic Effects of Nebivolol on Neonatal Cardiomyocyte Hypertrophy Models.
    Ozakca I
    J Cardiovasc Pharmacol; 2019 Mar; 73(3):155-164. PubMed ID: 30601193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AdipoRon prevents l-thyroxine or isoproterenol-induced cardiac hypertrophy through regulating the AMPK-related pathway.
    Hu X; Ou-Yang Q; Wang L; Li T; Xie X; Liu J
    Acta Biochim Biophys Sin (Shanghai); 2019 Jan; 51(1):20-30. PubMed ID: 30566571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bakuchiol protects against pathological cardiac hypertrophy by blocking NF-κB signaling pathway.
    Wang Z; Gao L; Xiao L; Kong L; Shi H; Tian X; Zhao L
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30242058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.